PubRank

Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 25114022)

Published in Ann Oncol on August 11, 2014

Authors

C Collen1, N Christian2, D Schallier3, M Meysman4, M Duchateau2, G Storme2, M De Ridder2

Author Affiliations

1: Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium ccollen@uzbrussel.be.
2: Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
3: Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
4: Department of Respiratory Medicine, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

Associated clinical trials:

Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma | NCT02805530

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | NCT03905317

Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer | NCT04758481

Articles citing this ↘

The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist (2016) 0.76

Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer? Ann Transl Med (2017) 0.75

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. Thorac Cancer (2015) 0.75

Oligometastatic non-small-cell lung cancer: current treatment strategies. Lung Cancer (Auckl) (2016) 0.75

Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res (2016) 0.75

Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. Transl Lung Cancer Res (2016) 0.75

Radiotherapy for Oligometastatic Lung Cancer. Front Oncol (2017) 0.75